Mesoblast has long been one of the sharemarket's most polarising companies. Now it faces a momentous month awaiting results from trials of a potentially life-saving treatment for COVID-19.
The Melbourne-based biotech is also hopeful of a regulatory breakthrough in the US which could see its treatment for a life-threatening inflammatory condition in children approved by the US Food and Drug Administration (FDA).
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
